No Data
No Data
Lanfeng Biochemical (002513.SZ) announced first-quarter results with a net loss of 30.51 million yuan
Lanfeng Biochemical (002513.SZ) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 378 million yuan, a year-on-year decrease of 0.94%. Net loss attributable to shareholders of listed companies was RMB 30.51 million. Net loss of $33.1505 million for non-recurring profit and loss attributable to shareholders of listed companies is deducted.
Zhitong A Share Sale Restriction and Release List | April 22
According to the Zhitong Finance App, the ban on restricted shares of 23 listed companies was lifted on April 22, with a total market value of about 56.627 billion yuan. Today's specific sales restrictions and unbanned shares are as follows: Stock abbreviation, stock code, restricted stock type, number of banned shares, Xingfa Group 600141, share incentives, 900,000, Dongan Power 600178, share incentives, restricted circulation, 44263, Wanbaoxin Software 600845, share incentives, limited circulation 135,200, Weixing shares 002003, corporate placement and listing of 132 million, nopsin 002215 shares, share incentives to limit circulation 1,144 million Lanfeng Biochemical 00
Lanfeng Biochemical (002513.SZ): The subsidiary plans to establish a second-level subsidiary, Tongliao Xuhe
Gelonghui, April 12, 丨 Lanfeng Biochemical (002513.SZ) announced that the company held the 11th meeting of the 7th board of directors on April 12, 2024 to review and pass the “Proposal on Foreign Investment by Subsidiaries” and “Proposal on Holding the Foreign Investment of Second-tier Subsidiaries”. The company holds the first-level subsidiary Anhui Xuhe New Energy Technology Co., Ltd. (“Xuhe Technology”) and the wholly-owned subsidiary Jiangsu Lanfeng Import & Export Co., Ltd. (“Lanfeng Import and Export”), to jointly invest abroad to establish a second-level subsidiary Tongliao Xuhe New Energy Technology Co., Ltd. (tentative name, hereinafter referred to as “Tongliao Technology”)
Xuhe Technology, a subsidiary of Lanfeng Biochemical (002513.SZ), filed a lawsuit over a sales contract dispute
Lanfeng Biochemical (002513.SZ) issued an announcement that the company's holding subsidiary, Anhui Xuhe New Energy Technology Co., Ltd. “...
Lanfeng Biochemical (002513.SZ): Pre-loss of 250 million yuan to 350 million yuan in 2023
Gelonghui, January 30, 丨 Lanfeng Biochemical (002513.SZ) announced its 2023 annual results forecast. Net profit loss attributable to shareholders of listed companies during the reporting period was 35 million yuan to 250 million yuan, loss of 320.6924 million yuan for the same period last year; net profit loss after deducting non-recurring profit and loss of 390 million yuan to 290 million yuan, loss of 25.637 million yuan for the same period last year; basic earnings loss per share was 0.93 yuan/share — 0.66 yuan/share. Reasons for changes in performance: 1. Long-term position of Ningxia Lanfeng Fine Chemical Co., Ltd., a wholly-owned subsidiary of the company
Solar N Plus Obtains BIS Certification for Its TOPCon Modules
CHUZHOU, China, Jan. 10, 2024 /PRNewswire/ -- Solar N Plus New Energy Technology Co., Ltd. (Solar N Plus), a leading manufacturing expert in TOPCon technology and a subsidiary of Lanfeng Bio-chemical
No Data